Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108


Risk of fracture with thiazolidinediones: disease or drugs?

Bazelier MT, Vestergaard P, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, de Vries F.

Calcif Tissue Int. 2012 Jun;90(6):450-7. doi: 10.1007/s00223-012-9591-8. Epub 2012 Apr 10.


Use of thiazolidinediones and risk of osteoporotic fracture: disease or drugs?

Bazelier MT, Gallagher AM, van Staa TP, Cooper C, Leufkens HG, Vestergaard P, de Vries F.

Pharmacoepidemiol Drug Saf. 2012 May;21(5):507-14. doi: 10.1002/pds.3234. Epub 2012 Mar 6.


Use of thiazolidinediones and risk of bladder cancer: disease or drugs?

Bazelier MT, de Vries F, Vestergaard P, Leufkens HG, De Bruin ML.

Curr Drug Saf. 2013 Nov;8(5):364-70.


Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.

Schwartz AV, Chen H, Ambrosius WT, Sood A, Josse RG, Bonds DE, Schnall AM, Vittinghoff E, Bauer DC, Banerji MA, Cohen RM, Hamilton BP, Isakova T, Sellmeyer DE, Simmons DL, Shibli-Rahhal A, Williamson JD, Margolis KL.

J Clin Endocrinol Metab. 2015 Nov;100(11):4059-66. doi: 10.1210/jc.2015-1215. Epub 2015 Aug 25.


Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: A retrospective population-based cohort study.

Driessen JH, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F.

Diabetes Obes Metab. 2017 Mar;19(3):421-428. doi: 10.1111/dom.12843. Epub 2017 Jan 19.


Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.

Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK.

J Clin Endocrinol Metab. 2010 Feb;95(2):592-600. doi: 10.1210/jc.2009-1385. Epub 2010 Jan 8.


Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.


Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.

Vallarino C, Perez A, Fusco G, Liang H, Bron M, Manne S, Joseph G, Yu S.

Clin Drug Investig. 2013 Sep;33(9):621-31. doi: 10.1007/s40261-013-0106-9.


Thiazolidinediones and fractures: evidence from translating research into action for diabetes.

Bilik D, McEwen LN, Brown MB, Pomeroy NE, Kim C, Asao K, Crosson JC, Duru OK, Ferrara A, Hsiao VC, Karter AJ, Lee PG, Marrero DG, Selby JV, Subramanian U, Herman WH.

J Clin Endocrinol Metab. 2010 Oct;95(10):4560-5. doi: 10.1210/jc.2009-2638. Epub 2010 Jul 14.


A cohort study of thiazolidinediones and fractures in older adults with diabetes.

Solomon DH, Cadarette SM, Choudhry NK, Canning C, Levin R, Stürmer T.

J Clin Endocrinol Metab. 2009 Aug;94(8):2792-8. doi: 10.1210/jc.2008-2157. Epub 2009 May 26.


Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].


The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.

Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.

Clin Ther. 2009 Nov;31(11):2665-77. doi: 10.1016/j.clinthera.2009.11.003.


Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.


Bone fracture risk is not associated with the use of glucagon-like peptide-1 receptor agonists: a population-based cohort analysis.

Driessen JH, Henry RM, van Onzenoort HA, Lalmohamed A, Burden AM, Prieto-Alhambra D, Neef C, Leufkens HG, de Vries F.

Calcif Tissue Int. 2015 Aug;97(2):104-12. doi: 10.1007/s00223-015-9993-5. Epub 2015 Apr 17.


Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.

Lin HC, Hsu YT, Kachingwe BH, Hsu CY, Uang YS, Wang LH.

J Clin Pharm Ther. 2014 Aug;39(4):354-60. doi: 10.1111/jcpt.12151. Epub 2014 Mar 24.


Glycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients.

Chen HH, Horng MH, Yeh SY, Lin IC, Yeh CJ, Muo CH, Sung FC, Kao CH.

PLoS One. 2015 Aug 28;10(8):e0135530. doi: 10.1371/journal.pone.0135530. eCollection 2015.


Use of thiazolidinediones and fracture risk.

Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR.

Arch Intern Med. 2008 Apr 28;168(8):820-5. doi: 10.1001/archinte.168.8.820.


Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture.

Driessen JH, van Onzenoort HA, Henry RM, Lalmohamed A, van den Bergh JP, Neef C, Leufkens HG, de Vries F.

Bone. 2014 Nov;68:124-30. doi: 10.1016/j.bone.2014.07.030. Epub 2014 Aug 2.


Risk of fracture with thiazolidinediones: an individual patient data meta-analysis.

Bazelier MT, de Vries F, Vestergaard P, Herings RM, Gallagher AM, Leufkens HG, van Staa TP.

Front Endocrinol (Lausanne). 2013 Feb 26;4:11. doi: 10.3389/fendo.2013.00011. eCollection 2013.


Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Stockl KM, Le L, Zhang S, Harada AS.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.


Supplemental Content

Support Center